Test Catalog

Test Id : TRCHG

ToRCH Profile IgG, Serum

Useful For
Suggests clinical disorders or settings where the test may be helpful

Determination of immune status of individuals to the rubella virus following vaccination or prior exposure

 

As an indication of past or recent infection with Toxoplasma gondii, cytomegalovirus, or herpes simplex virus (HSV)

 

Distinguishing between infection caused by HSV types 1 and 2, especially in patients with subclinical or unrecognized HSV infection

Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test Id Reporting Name Available Separately Always Performed
TOXGP Toxoplasma Ab, IgG, S Yes Yes
RBPG Rubella Ab, IgG, S Yes Yes
CMVG Cytomegalovirus Ab, IgG, S Yes Yes
HS1G HSV Type 1 Ab, IgG, S No Yes
HS2G HSV Type 2 Ab, IgG, S No Yes

Method Name
A short description of the method used to perform the test

Multiplex Flow Immunoassay

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Torch Profile IgG, S

Aliases
Lists additional common names for a test, as an aid in searching

Rubella

Toxoplasma

Cytomegalovirus (CMV)

Herpes Simplex Virus (HSV)

Specimen Type
Describes the specimen type validated for testing

Serum

Ordering Guidance

To evaluate recent or acute infection with Toxoplasma gondii, order TXM / Toxoplasma gondii Antibody, IgM, Serum.

 

For patients presenting with presumed acute infection with herpes simplex virus (HSV), order HERPB / Herpes Simplex Virus 1 and 2, Qualitative PCR, Blood.

 

IgG antibodies in patients younger than 6 months of age are typically the result of passive transfer from the mother. To assess possible infection in patients less than 6 months old, consider ordering the IgM testing.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL

Collection Instructions: Centrifuge and aliquot serum into plastic vial.

Forms

If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

1.2 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Heat-inactivated specimen Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
Frozen 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Determination of immune status of individuals to the rubella virus following vaccination or prior exposure

 

As an indication of past or recent infection with Toxoplasma gondii, cytomegalovirus, or herpes simplex virus (HSV)

 

Distinguishing between infection caused by HSV types 1 and 2, especially in patients with subclinical or unrecognized HSV infection

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Toxoplasma gondii:

Toxoplasma gondii is an obligate intracellular protozoan parasite that is capable of infecting a variety of intermediate hosts including humans. Infected definitive hosts (cats) shed oocysts in feces that rapidly mature in the soil and become infectious.(1) Toxoplasmosis is acquired by humans through ingestion of food or water contaminated with cat feces or through eating undercooked meat containing viable oocysts. Vertical transmission of the parasite through the placenta can also occur, leading to congenital toxoplasmosis. Following primary infection, T gondii can remain latent for the life of the host; the risk for reactivation is highest among immunosuppressed individuals.

 

Seroprevalence studies performed in the United States indicate that approximately 9% to 11% of individuals between the ages of 6 and 49 have antibodies to T gondii.(2) Infection of immunocompetent adults is typically asymptomatic. In symptomatic cases, patients most commonly present with lymphadenopathy and other nonspecific constitutional symptoms, making definitive diagnosis difficult to determine.

 

Severe-to-fatal infections can occur among patients with AIDS or individuals that are otherwise immunosuppressed. These infections are thought to be caused by reactivation of latent infections and commonly involved the central nervous system.(3)

 

Transplacental transmission of the parasites resulting in congenital toxoplasmosis can occur during the acute phase of acquired maternal infection. The risk of fetal infection is a function of the time at which acute maternal infection occurs during gestation.(4) The incidence of congenital toxoplasmosis increases as pregnancy progresses; conversely, the severity of congenital toxoplasmosis is greatest when maternal infection is acquired early during pregnancy. A majority of infants infected in utero are asymptomatic at birth, particularly if maternal infection occurs during the third trimester, with sequelae appearing later in life. Congenital toxoplasmosis results in severe generalized or neurologic disease in about 20% to 30% of the infants infected in utero; approximately 10% exhibit ocular involvement only and the remainder are asymptomatic at birth. Subclinical infection may result in premature delivery and subsequent neurologic, intellectual and audiologic defects.

 

Rubella:

Rubella (German or 3-day measles) is a member of the Togavirus family, and humans remain the only natural host for this virus. Transmission is typically through inhalation of infectious aerosolized respiratory droplets, and the incubation period following exposure can range from 12 to 23 days.(5) Infection is generally mild, self-limited and characterized by a maculopapular rash beginning on the face and spreading to the trunk and extremities, fever, malaise, and lymphadenopathy.(6)

 

Primary, in utero rubella infections can lead to severe sequelae for the fetus, particularly if infection occurs within the first 4 months of gestation. Congenital rubella syndrome is often associated with hearing loss, cardiovascular and ocular defects.(7)

 

The United States 2-dose measles, mumps, rubella (MMR) vaccination program, which calls for vaccination of all children, leads to seroconversion in 95% of children following the first dose.(5) A total of 4 cases of rubella were reported to the Centers for Disease Control and Prevention (CDC) in 2011 without any cases of congenital rubella syndrome.(8) Due to the success of the national vaccination program, rubella is no longer considered endemic in the United States (cdc.gov/rubella). However, immunity may wane with age as approximately 80% to 90% of adults will show serologic evidence of immunity to rubella.

 

Cytomegalovirus:

Cytomegalovirus (CMV) is a member of the Herpesviridae family of viruses and usually causes asymptomatic infection after which it remains latent in patients, primarily within bone marrow derived cells.(9) Primary CMV infection in immunocompetent individuals may also manifest as a mononucleosis-type syndrome, similar to primary Epstein-Barr virus infection, with fever, malaise, and lymphadenopathy.

 

CMV is a significant cause of morbidity and mortality among bone marrow or solid organ transplant recipients, individuals with AIDS, and other immunosuppressed patients due to virus reactivation or from a newly acquired infection.(10,11) Infection in these patient populations can affect almost any organ and lead to multi-organ failure. CMV is also responsible for congenital disease among newborns and is 1 of the ToRCH infections (toxoplasmosis, other infections including syphilis, rubella, CMV, and herpes simplex virus [HSV]).

 

CMV seroprevalence increases with age. In the United States, the prevalence of CMV-specific antibodies increases from approximately 36% to over 91% in children between the ages of 6 and 11 and adults over 80 years old, respectively.(12)

 

Herpes Simplex Virus Types 1 and 2:

HSV types 1 and 2 are members of the Herpesviridae family and produce infections that may range from mild stomatitis to disseminated and fatal disease. Clinical conditions associated with HSV infection include gingivostomatitis, keratitis, encephalitis, vesicular skin eruptions, aseptic meningitis, neonatal herpes, genital tract infections, and disseminated primary infection.

 

Infections with HSV types 1 and 2 can differ significantly in their clinical manifestations and severity. HSV type 2 primarily causes urogenital infections and is found almost exclusively in adults. HSV type 1 is closely associated with orolabial infection, although genital infection with this virus can be common in certain populations.

 

The diagnosis HSV infections is routinely made based on clinical findings and supported by laboratory testing using polymerase chain reaction (PCR) or viral culture. However, in instances of subclinical or unrecognized HSV infection, serologic testing for IgG-class antibodies to type-specific HSV glycoprotein G (gG) may be useful. There are several circumstances in which it may be important to distinguish between infection caused by HSV types 1 and 2.(13) For example, the risk for reactivation is highest for HSV type 2 and the method of antiviral therapy may be different depending on the specific type of HSV causing disease. In addition, the results of HSV type specific IgG testing is sometimes used during pregnancy to identify risks of congenital HSV disease and allow for focused counseling prior to delivery.(14,15)

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Toxoplasma ANTIBODY, IgG

Negative

 

Toxoplasma IgG

< or =9 IU/mL (Negative)

10-11 IU/mL (Equivocal)

> or =12 IU/mL (Positive)

 

RUBELLA ANTIBODY, IgG

Vaccinated: Positive (> or =1.0 AI)

Unvaccinated: Negative (< or =0.7 AI)

 

CYTOMEGALOVIRUS

Negative

 

HERPES SIMPLEX VIRUS (HSV), TYPE 1 AND TYPE 2 ANTIBODIES, IgG

Herpes Simplex Virus (HSV) Type 1, IgG

Negative

 

Herpes Simplex Virus (HSV) Type 2, IgG

Negative

Interpretation
Provides information to assist in interpretation of the test results

Toxoplasma gondii:

A positive Toxoplasma IgG result is indicative of current or past infection with T gondii. A single positive Toxoplasma IgG result should not be used to diagnose recent infection.

 

Equivocal Toxoplasma IgG results may be due to very low levels of circulating IgG during the acute stage of infection. A second specimen should be submitted for testing if clinically indicated.

 

Individuals with negative Toxoplasma IgG results are presumed to not have had previous exposure to T gondii. However, negative results may be seen in cases of remote exposure with subsequent loss of detectable antibody. Seroconversion from negative to positive IgG is indicative of T gondii infection subsequent to the first negative specimen.

 

Rubella:

Positive: The presence of detectable IgG-class antibodies to rubella indicates prior exposure through infection or immunization. Individuals testing positive for IgG-class antibodies to rubella are considered immune.

 

Equivocal: Submit an additional specimen for testing in 10 to 14 days to demonstrate IgG seroconversion if recently vaccinated or if otherwise clinically indicated.

 

Negative: The absence of detectable IgG-class antibodies to rubella suggests no prior exposure to this virus or the lack of a specific immune response to immunization.

 

Cytomegalovirus:

Positive cytomegalovirus (CMV) IgG results indicate past or recent CMV infection. These individuals may transmit CMV to susceptible individuals through blood and tissue products.

 

Equivocal CMV IgG results may occur during acute infection or may be due to nonspecific binding reactions. Submit an additional specimen for testing if clinically indicated.

 

Individuals with negative CMV IgG results are presumed to not have had prior exposure or infection with CMV and are therefore considered susceptible to primary infection.

 

Herpes Simplex Virus:

The presence of IgG-class antibodies to herpes simplex virus (HSV) types 1 or 2 indicates previous exposure and does not necessarily indicate that HSV is the causative agent of an acute illness.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Toxoplasma gondii:

Sera drawn very early during the acute stage of infection may have Toxoplasma IgG levels less than 9 IU/mL.

 

The Toxoplasma IgG assay should not be used alone to diagnose recent T gondii infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings.

 

The performance characteristics of this assay have not been evaluated in immunocompromised individuals and have not been established for cord blood or for testing of neonates.

 

Rubella:

Specimens drawn early during the acute phase of infection or shortly (1-2 weeks) following vaccination may be negative for IgG class antibodies.

 

Cytomegalovirus:

Sera drawn very early during the acute stage of infection may have undetectable levels of cytomegalovirus (CMV) IgG.

 

The CMV IgG assay should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected diseases, submit a second specimen for testing in 10 to 14 days.

 

The performance characteristics of this assay have not been evaluated in immunosuppressed or organ transplant recipients and have not been established for cord blood or for testing of neonates.

 

Immune complexes or other immunoglobulin aggregates present in patient specimen may cause increased nonspecific binding and produce false-positive results.

 

Potential cross-reactivity for CMV with human chorionic gonadotropin, HIV IgG, multiple myeloma IgG, rheumatoid factor IgM, and Toxoplasma gondii IgG have not be ruled out.

 

Herpes Simplex Virus Types 1 and 2:

Detection of IgG-class antibodies to herpes simplex virus (HSV) should not be used routinely as the primary means of diagnosing HSV infection. For patients presenting with presumed acute infection with HSV, a clinical specimen (eg, oral, dermal, or genital lesion) should be sampled and submitted for detection of HSV types 1 and 2 by rapid polymerase chain reaction (PCR) (HERPB / Herpes Simplex Virus 1 and 2, Qualitative PCR, Blood).

 

Serum specimens drawn too early in the course of infection may not have detectable levels of HSV IgG. In cases of suspected early disease, a repeat serum specimen should be drawn 14 to 21 days later and submitted for testing.

 

The presence of IgG-class antibodies to either HSV type 1 or 2 does not differentiate between remote infection and acute disease.

 

HSV serology cannot distinguish genital from nongenital infections.

 

The predictive value of positive or negative results depends on the prevalence of disease and the pretest likelihood of HSV type 1 and HSV type 2. False-positive results may occur. Repeat testing, or testing by a different method, may be indicated in some settings (eg, patients with low likelihood of HSV infection).

Supportive Data

Toxoplasma gondii:

To evaluate the accuracy of the BioPlex Toxoplasma IgG multiplex flow immunoassay, 600 prospective serum samples submitted for routine Toxoplasma IgG testing by the VIDAS enzyme-linked fluorescence immunoassay (ELFA; bioMerieux) were also analyzed in a blinded fashion by the BioPlex assay within a 24-hour period. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further resolution of discrepant results was performed by sending the samples to the Palo Alto Medical Foundation for testing. The results are summarized below: 

 

 

Toxoplasma IgG (VIDAS ELFA)

BioPlex Toxoplasma IgG

 

Positive

Negative

Equivocal

Positive

63

2(a)

6

Negative

0

528

0

Equivocal

0

0

1

(a) Both of these serum samples were negative by the Sabin-Feldman dye test at the Palo Alto Medical Foundation Toxoplasma laboratory.

Sensitivity: 100% (63/63); 95% CI: 93.1% to 100%

Specificity: 99.6% (528/530); 95% CI: 98.5% to 99.9%

Overall Percent Agreement: 98.7% (592/600); 95% CI: 97.3% to 99.4%

 

Rubella:

To evaluate the accuracy of the BioPlex Rubella IgG multiplex flow immunoassay (MFI), 500 prospective serum samples were analyzed in a blinded fashion by the SeraQuest Rubella IgG IEA (Quest International) and the BioPlex Rubella IgG assay. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further discrepancies were evaluated by the Rubella IgG VIDAS enzyme-linked fluorescent immunoassay (ELFA; bioMerieux, Inc.). The results are summarized below:

 

 

SeraQuest Rubella IgG EIA

BioPlex Rubella IgG

 

Positive

Negative

Equivocal

Positive

446

0

0

Negative

7(a)

23

4

Equivocal

17

0

3

(a) 6/7 samples tested as equivocal by the VIDAS Rubella IgG ELFA.

Sensitivity: 94% (446/470); 95% CI: 92.5% to 96.6%

Specificity: 100% (23/23); 95% CI: 83.1% to 100%

Overall Percent Agreement: 94.4% (472/500); 95% CI: 92.0% to 96.1% 

 

Cytomegalovirus:

To evaluate the accuracy of the BioPlex cytomegalovirus (CMV) IgG multiplex flow immunoassay, 598 prospective serum samples submitted for routine CMV IgG testing by the VIDAS enzyme-linked fluorescence immunoassay (ELFA; bioMerieux) were also analyzed in a blinded fashion by the BioPlex assay within a 24-hour period. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further resolution of discrepant results was performed by using the Diamedix CMV IgG enzyme immunoassay. The results are summarized below:

 

 

CMV IgG (VIDAS ELFA)

BioPlex CMV IgG

 

Positive

Negative

Equivocal

Positive

336

2(a)

0

Negative

3(b)

254

3

Equivocal

0

0

0

(a) Both of these serum samples were negative by the Diamedix CMV IgG EIA

(b) All 3 of these serum samples were negative by the Diamedix CMB IgG EIA

Sensitivity: 99.1% (336/339); 95% CI: 97.3% to 99.8%

Specificity: 99.2% (254/256); 95% CI: 97.0% to 100%

Overall Percent Agreement: 98.7% (590/598); 95% CI: 97.3% to 99.4%

 

Herpes Simplex Virus Type 1:

To evaluate the accuracy of the BioPlex HSV assay, 505 prospective serum samples were tested by EIA (HerpeSelect, Focus Diagnostics) and the BioPlex HSV-1/2 IgG assay. Samples that had discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further discrepancies were evaluated by glycoprotein G (gG) type-specific Western blot (WB) at the University of Washington Virology laboratory. The results are summarized in Tables 1 and 2 below:

 

Table 1.

HSV-1 by HerpeSelect EIA

BioPlex HSV-1 IgG

 

Positive

Negative

Equivocal

Positive

254

5(a)

0

Negative

2(b)

240

1

Equivocal

0

3

0

(a) All 5 specimens were positive by WB

(b) Both of these specimens were positive by WB

Sensitivity: 99.2% (254/256); 95% CI: 97.0% to 99.9%

Specificity: 96.8% (240/248); 95% CI: 93.7% to 98.5%

Overall Percent Agreement: 97.8% (494/505); 95% CI: 96.1% to 98.8% 

 

Table 2.

HSV-2 by HerpeSelect EIA

BioPlexHSV-2 IgG

 

Positive

Negative

Equivocal

Positive

115

9(a)

2

Negative

1(b)

376

0

Equivocal

1

1

0

(a) Two of these 9 specimens were positive by WB, 2 of these 9 specimens were equivocal by WB.

(b) This specimen was negative by WB

Sensitivity: 98.3% (115/117); 95% CI: 93.6% to 99.9%

Specificity: 97.4% (376/386); 95% CI: 95.2% to 98.7%

Overall Percent Agreement: 97.2% (376/386); 95% CI: 95.4% to 98.4%

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Tenter AM, Heckeroth AR, Weiss LM: Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12-13):1217-1258

2. Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M: Toxoplasma gondii infection in the United States, 1999-2004, decline from the prior decade. Am J Trop Med Hyg. 2007;77(3):405-410

3. Luft BJ, Remigton JS: Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15(2):211-222

4. Wong SY, Remington JS: Toxoplasmosis in pregnancy. Clin Infect Dis. 1994;18(6):853-861

5. AAP Committee on Infectious Diseases: Rubella. In: Pickering LK, Baker CJ, Kimberlin DW, eds. Red Book. 2012 Report of the Committee on Infectious Diseases. 29th ed. American Academy of Pediatrics; 2012

6. Best JM: Rubella. Semin Fetal Neonatal Med. 2007;12(3):182-192

7. Duszak RS: Congenital rubella syndrome-major review. Optometry. 2009:80(1):36-43

8. Notifiable Diseases and Mortality Tables. MMWR Morb Mortal Wkly Rep. 2012;61(34):466-479

9. Soderberg-Naucler C, Fish KN, Nelson JA: Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119-126

10. Kusne S, Shapiro R, Fung J: Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis. 1999;1(3):187-203

11. Rubin RH: Importance of CMV in the transplant population. Transpl Infect Dis. 1999;1(1):3-7

12. Staras SA, Dollard SC, Radford KW, et al: Seroprevalence of cytomegalovirus infection in the United States, 1998-1994. Clin Infect Dis. 2006;43(9):1143-1151

13. Ashley RL, Wald A: Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev. 1999;12:1-8

14. Ashley RL, Wu L, Pickering JW, et al: Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol. 1998;36:294-295

15. Brown ZA, Selke S, Zeh J, et al: The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509-515

16. Binnicker MJ, Jespersen DJ, Harring JA: Comparative evaluation of three multiplex flow immunoassays to enzyme immunoassay for the detection and differentiation of IgG-class antibodies to Herpes Simplex Virus types 1 and 2. Clin Vaccine Immunol. 2010;17(2):253-257

Method Description
Describes how the test is performed and provides a method-specific reference

Detection of IgG-class antibodies to Toxoplasma gondii, rubella, cytomegalovirus, and herpes simplex virus types 1 and 2 is performed on the BioPlex 2200 system, which uses multiplex flow immunoassay technology. Five different populations of fluorescent dyed beads are each coated with antigens unique to each infectious organism. Patient sample is combined with sample diluent and the 5 bead set and incubated at 37 degrees C. During this time IgG antibodies will bind to the antigen-coated beads. After a wash cycle, a fluorescently labeled antihuman IgG antibody conjugate is added to the mixture and incubated at 37 degrees C. Following a wash step to remove unbound conjugate, the bead mixture is passed through a detector that identifies the bead based on dye fluorescence and determines the amount of antibody captured by the antigen based on fluorescence of the antihuman IgG conjugate. Raw data are calculated in relative fluorescence intensity and is converted to an antibody index (AI) for interpretation. Three additional dyed beads, an internal standard bead, a serum verification bead, and a reagent black bead are present in each reaction mixture to verify detector response, the addition of serum to the reaction vessel and the absence of significant nonspecific binding in serum, respectively.(Package inserts: BioPlex 2200 System, ToRC IgG. Bio-Rad Laboratories; 03/2012; BioPlex 2200 System, MMRV IgG. 11/30/2018)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Saturday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

Same day/1 to 3 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

86644-CMV

86695-Herpes simplex, type 1

86696-Herpes simplex, type 2

86762-Rubella

86777-Toxoplasma

LOINC® Information

Test Id Test Order Name Order LOINC Value
TRCHG Torch Profile IgG, S In Process
Result Id Test Result Name Result LOINC Value
Result LOINC Value Tooltip

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports